Adaptive Biotechnologies Corporation
General ticker "ADPT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.2B (TTM average)
Adaptive Biotechnologies Corporation follows the US Stock Market performance with the rate: 51.2%.
Estimated limits based on current volatility of 2.6%: low 24.26$, high 25.57$
Factors to consider:
- Total employees count: 624 (+0.8%) as of 2025
- Top business risk factors: Net losses, Market acceptance, Strategic risks and growth management, Lab errors, Government regulation
- Current price 17.0% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [10.87$, 21.08$]
- 2026-12-31 to 2027-12-31 estimated range: [9.24$, 18.58$]
Financial Metrics affecting the ADPT estimates:
- Negative: with PPE of -41.7 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -1.82 <= 0.28
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Investing cash flow per share per price, % of 1.50 > -0.64
- Positive: 42.26 < Shareholder equity ratio, % of 42.67 <= 63.63
- Negative: 0.01 < Interest expense per share per price, % of 0.47
Short-term ADPT quotes
Long-term ADPT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $170.28MM | $178.96MM | $276.98MM |
| Operating Expenses | $397.31MM | $341.51MM | $334.10MM |
| Operating Income | $-227.03MM | $-162.55MM | $-57.12MM |
| Non-Operating Income | $1.73MM | $2.95MM | $-2.33MM |
| Interest Expense | $13.80MM | $11.58MM | $11.78MM |
| R&D Expense | $122.12MM | $102.95MM | $93.77MM |
| Income(Loss) | $-225.30MM | $-159.59MM | $-59.46MM |
| Net Income(Loss)* | $-225.25MM | $-159.49MM | $-59.50MM |
| Stockholders Equity | $308.40MM | $202.71MM | $218.79MM |
| Inventory | $14.45MM | $8.44MM | $9.82MM |
| Assets | $661.13MM | $539.38MM | $512.74MM |
| Operating Cash Flow | $-156.32MM | $-95.21MM | $-45.99MM |
| Capital expenditure | $10.70MM | $3.66MM | $2.96MM |
| Investing Cash Flow | $129.65MM | $77.79MM | $37.95MM |
| Financing Cash Flow | $2.25MM | $0.24MM | $30.40MM |
| Earnings Per Share** | $-1.56 | $-1.08 | $-0.39 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.